Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
Last trade$11.76
Day change+$0.13 (+1.12%)
Day range$11.40 – $12.04
Volume1,655,940
Market cap$2.54B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.54B
Price / earnings
8.3×
Price / book
7.53×
Price / sales
0.95×
EV / sales
1.44×
EV / EBITDA
11.81×
Profitability
Earnings per share
$1.40
Return on assets
13.87%
Return on equity
90.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.45×
Current ratio
1.23×
Quick ratio
1.23×
Cash ratio
0.43×
Cash flow
Price / cash flow
12.26×
Price / free cash flow
12.86×
Free cash flow
$197.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVAH, quarterly periods
Line item
Q3 FY2026 Oct 3, 2026
Q2 FY2026 Jul 4, 2026
Q1 FY2026 Apr 4, 2026
Q4 FY2025 Jan 3, 2026
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 28, 2024
Revenue
$695.54M
$670.48M
$647.92M
$662.48M
$621.94M
$589.55M
$559.22M
$519.87M
Cost of revenue
$468.78M
$451.96M
$442.49M
$449.18M
$419.12M
$378.75M
$375.67M
$348.15M
Gross profit
$226.77M
$218.53M
$205.43M
$213.3M
$202.82M
$210.8M
$183.56M
$171.72M
Selling, general and administrative
$103.48M
$97.08M
$95.79M
-$26.39M
$95.4M
$90.07M
$91.39M
-$3.24M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$143.21M
$138.55M
$136.1M
$142.25M
$149.24M
$130.77M
$131.76M
$125.95M
Operating income
$83.56M
$79.98M
$69.33M
$71.05M
$53.58M
$80.03M
$51.8M
$45.77M
Interest expense
-$27.09M
-$27.78M
-$29.16M
-$32.62M
-$35.13M
-$36M
-$36.34M
-$38.1M
Income before taxes
$64.78M
$56.47M
$44.98M
$39.25M
$13.42M
$44.14M
$10.15M
$26.94M
Income taxes
$19.33M
$16.18M
$3.32M
-$139.51M
-$647K
$17.11M
$4.96M
-$2.25M
Net income
$45.45M
$40.29M
$41.65M
$178.75M
$14.06M
$27.03M
$5.19M
$29.18M
Net income attributable to common shareholders
$45.45M
$40.29M
$41.65M
$178.75M
$14.06M
$27.03M
$5.19M
$29.18M
EBITDA
$87.39M
$87.22M
$75.48M
$75.26M
$55.01M
$86.05M
$54.5M
$49.56M
Basic earnings per share
$0.21
$0.19
$0.19
$0.85
$0.07
$0.13
$0.03
$0.15
Diluted earnings per share
$0.20
$0.18
$0.19
$0.81
$0.06
$0.13
$0.03
$0.15
Recent news
Company coverage with links to the original publishers.
Zacks identifies Aveanna Healthcare (AVAH) as an attractive value stock opportunity, citing its Zacks Rank #2 (Buy) rating and Value grade of A. The company's Forward P/E ratio of 17.55 is below its industry average of 19.90, and its P/S ratio of 1.0 compares favorably to the industry average of 1.53, suggesting the stock may be undervalued relative to its earnings outlook.
Aveanna Healthcare reported Q3 2026 earnings of $0.23 per share, beating consensus estimates of $0.20, with revenues of $695.54 million exceeding expectations by 1.81%. The company has outperformed market estimates in four consecutive quarters and gained 60.2% year-to-date. Aveanna received a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Meanwhile, Agilent Technologies is expected to report Q3 2026 results on November 23, with projected earnings of $1.72 per share (+8.2% YoY) and revenues of $1.99 billion (+6.7% YoY), though consensus estimates were revised 1% lower in the last 30 days.
LifeStance Health Group (LFST) reported Q3 2026 earnings of $0.06 per share, doubling the consensus estimate of $0.03, with revenues of $455.86 million exceeding expectations by 6.31%. The stock has gained 101.9% year-to-date, significantly outperforming the S&P 500's 12.3% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
RadNet (RDNT) surged 9.7% to $80.26 on investor optimism ahead of its third-quarter 2026 earnings release on November 9. The medical diagnostic imaging operator is expected to report $0.21 EPS and $637.56M in revenue, up 21.9% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to sustain momentum without further positive estimate revisions. RadNet carries a Zacks Rank #3 (Hold).
Chemed reported Q3 2026 earnings of $6.75 per share, beating consensus estimates of $6.39, with revenues of $690.94 million exceeding expectations. Despite the beat and 19.9% year-to-date outperformance versus the S&P 500, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The Medical - Outpatient and Home Healthcare industry ranks in the bottom 36% of Zacks industries.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.